Metoprolol succinate combination in the treatment of hypertension

Angiology

Volumn 60, Issue 5, 2009, Pages 608-613

  Papadopoulos, Dimitris P ^a,b   Papademetriou, Vasilios ^a,b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Hypertension; Metoprolol succinate hydrochlorothiazide

Indexed keywords

AMLODIPINE BESYLATE; ATENOLOL; C REACTIVE PROTEIN; CHOLESTEROL; FELODIPINE; FELODIPINE PLUS METOPROLOL; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS METOPROLOL; HYDROCHLOROTHIAZIDE PLUS METOPROLOL SUCCINATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; PERINDOPRIL; PLACEBO; RAMIPRIL; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; BIOEQUIVALENCE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DIFFUSION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; REVIEW; RISK REDUCTION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TABLET DISINTEGRATION; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DIURETICS; DRUG COMBINATIONS; HUMANS; HYPERTENSION; METOPROLOL; RECEPTORS, ADRENERGIC, BETA-1; TREATMENT OUTCOME;

EID: 70350510303     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319708326450     Document Type: Review

References (23)

1. Vidt DG. Contributing factors in resistant hypertension. Truly refractory disease is rarely found in a properly conducted workup. Postgrad Med. 2000 ; 107: 57-60, 63-64, 67-68, 70.
2. Fields LE, Burt VL, Cutler JA, Hughes J., Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004 ; 44: 398-404.
3. Papadopoulos DP, Papademetriou V. Resistant hypertension: diagnosis and management. J Cardiovasc Pharmacol Ther. 2006 ; 11: 113-118.
4. Neal B., MacMahon S., Chapman N. Blood Pressure Lowering Treatment Trialistsĝ€™ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialistsĝ€™ Collaboration. Lancet. 2000 ;356: 1955-1964.
5. Cushman WC, Ford CE, Cutler JA, et al. ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 ; 4: 393-404.
6. Jordo L., Johnsson G., Lundborg P., Persson BA, RegCurrency signrdh CG, RÖnn O. Bioavailability and disposition of metoprolol and hydrochlorothiazide combined in one tablet and of separate doses of hydrochlorothiazide. Br J Clin Pharmacol. 1979 ; 7: 563-567.
7. Darmansjah I., Wong E., Setiawati A., et al. Pharmacokinetic and pharmacodynamic properties of controlled release (CR/ZOK) metoprolol in healthy Oriental subjects: a comparison with conventional formulations of metoprolol and atenolol. J Clin Pharmacol. 1990 ; 30: S39 - S45.
8. Sandberg A., Ragnarsson G., Jonsson UE, SjÖgren J. Design of a new multiple-unit controlled-release formulation of metoprolol-metoprolol CR. Eur J Clin Pharmacol. 1988 ; 33: S3 - S7.
9. Plosker GL, Clissold SP Controlled release metoprolol formulations: a review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease. Drugs. 1992 ; 43: 382-414.
10. Wikstrand J., Andersson B., Kendall MJ, Stanbrook H., Klibaner M. Pharmacokinetic considerations of formulation: extended-release metoprolol succinate in the treatment of heart failure. J Cardiovasc Pharmacol. 2003 ; 41: 151-157.
11. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000 ;283: 1967-1975.
12. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 ;289: 2560-2572.
13. Hajjar I., Kotchen TA Trends in prevalence, awareness, treatment and control of hypertension in the United States, 1988-2000. JAMA. 2003 ; 290: 199-206.
14. Papademetriou V., Hainer JW, Sugg J., Munzer D. ATTACH Study Group. Factorial antihypertensive study of an extended-release metoprolol and hydrochlorothiazide combination. Am J Hypertens. 2006 ; 19: 1217-1225.
15. Mancia G., De Backer G., Dominiczak A., et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007 ; 25: 1105-1187. (Pubitemid 46924065)
16. Mancia G., De Backer G., Dominiczak A., et al. The task force for the management of arterial hypertension of the European Society of Hypertension; The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007 ; 28: 1462-1536.
17. Sarafidis P., Bogojevic Z., Basta E., Kirstner E., Bakris GL Comparative efficacy of two different beta-blockers on 24-hour blood pressure control. J Clin Hypertens (Greenwich). 2008 ; 10: 112-118.
18. Frishman WH, Hainer JW, Sugg J. M-FACT Study Group. A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT). Am J Hypertens. 2006 ; 19: 388-395.
19. Batisky DL, Sorof JM, Sugg J., et al. Toprol-XL Pediatric Hypertension Investigators. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J Pediatr. 2007 ; 150: 134-139.
20. Celik T., Iyisoy A., Acikel C., et al. The comparative effects of metoprolol and perindopril on aortic elasticity in young patients with prehypertension. Blood Press Monit. 2008 ; 13: 169-176.
21. Falkner B., Francos G., Kushner H. Metoprolol succinate, a selective beta-adrenergic blocker, has no effect on insulin sensitivity. J Clin Hypertens (Greenwich). 2006 ; 8: 336-343.
22. Thornley-Brown D., Wang X., Wright JT Jr, et al. Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease. Arch Intern Med. 2006 ; 166: 797-805.
23. King DE, Egan BM, Mainous AG, et al. The effect of extended-release metoprolol succinate on C-reactive protein levels in persons with hypertension. J Clin Hypertens (Greenwich). 2006 ; 8: 257-260.